Abstract
Tumor necrosis factor-α (TNF-α) plays an important role in inflammatory responses and immune system diseases. TNF-α inhibitors, including etanercept, infliximab and adalimumab, have become the effective therapies of some diseases such as rheumatoid arthritis, glomerular disease, psoriasis, and inflammatory bowel diseases. With the popularization of their clinical applications, there are more and more reports of new-onset or aggravated psoriasis caused by TNF-α inhibitors. This kind of adverse reactions may be related to cytokine imbalance among TNF-α, interleukins, and interferon etc., as well as to the genetic susceptibility. Types of TNF-α inhibitors and the blood concentration may also have contributions to the development of psoriasis. Key words: Tumor necrosis factors; Psoriasis; Drug-related side effects and adverse reactions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
